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The interest in biopreservation of food has prompted the quest for new natural 27 
antimicrobial compounds from different origins. Bacteriocins have been widely 28 
recognized as natural food biopreservatives but lastest advances on bateriocin biology 29 
have opened new fields to explore. On the contrary, the use of bacteriophages and 30 
endolysins has only been considered in the last five years and recent developments have 31 
produced promising perspectives. This review provides an overview of the current and 32 
foreseen applications of bacteriocins, bacteriophages and phage-encoded endolysins 33 








Food borne diseases are among the most serious and costly public health 41 
concerns worldwide, being a major cause of morbidity. In spite of modern technologies, 42 
good manufacturing practices, quality control and hygiene and safety concepts such as 43 
risk assessment and HACCP, the reported numbers of food-borne illnesses and 44 
intoxications still increased over the past decade. The most common food-borne 45 
infections in the European Union (EU) are caused by bacteria, namely Campylobacter, 46 
Salmonella and Listeria, and viruses. They are reported to affect over 380,000 EU 47 
citizens each year (EFSA, 2009). 48 
Food market globalization, the introduction of novel foods, new manufacturing 49 
processes and the growing demand for minimally processed, fresh-cut and ready-to-eat 50 
products may require a longer and more complex food chain, increasing the risk of 51 
microbiological contamination. Thus, novel and complementary food preservation 52 
technologies that comply with these demands from “farm to fork” are continuously 53 
seeked. Among alternative food preservation technologies, particular attention has been 54 
paid to biopreservation to extent the shelf-life and to enhance the hygienic quality, 55 
minimizing the impact on the nutritional and organoleptic properties of perishable food 56 
products. Biopreservation rationally exploits the antimicrobial potential of naturally 57 
occurring (micro-) organisms in food and/or their metabolites with a long history of safe 58 
use. Bacteriocins, bacteriophages and bacteriophage-encoded enzymes fall in this 59 
concept. This review will summarize basic knowledge and current applications of these 60 
natural antimicrobials along the food chain. Based on this state-of-the-art, future trends 61 
and areas of research that deserve more attention will be discussed.  62 
 63 
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Bacteriocins: structure and mode of action 64 
Bacteriocins are bacterial ribosomally synthesized peptides or proteins with 65 
antimicrobial activity. They were primarily described in E. coli (colicins). Most of the 66 
colicins are relatively large proteins (up to 80 kDa) that kill very closely related bacteria 67 
upon binding to the inner membrane or other cytosolic targets (Cascales et al., 2007). 68 
Nowadays, the term bacteriocin is mostly used to describe the small, heat-stable cationic 69 
peptides synthesised by Gram positive bacteria, namely lactic acid bacteria (LAB), 70 
which display a wider spectrum of inhibition (Cotter, Hill, & Ross, 2005). Since LAB 71 
have been traditionally associated to food and are regarded as safe, food biopreservation 72 
has mostly focused on LAB bacteriocins. 73 
 Bacteriocins comprise a very heterogeneous group regarding their primary 74 
structure, composition and physico-chemical properties. A “universal” classification of 75 
bacteriocins is still a matter of debate. A scheme has been recently proposed by Heng & 76 
Tagg (2006) which evolves from previous classification schemes and takes into account 77 
the nature of colicins. Thereby, bacteriocins are grouped in four main classes (Table 1). 78 
 Class I or lantibiotics include post-translationally modified peptides 79 
characterized by the distinctive thioether-based intramolecular rings of lanthionine and 80 
β-methyl-lanthionine (Xie & van der Donk, 2004). Class II encompasses heat stable 81 
non-modified peptides and is by far the largest class among Gram positive bacteriocins. 82 
In general, they are short cationic peptides with high isoelectric points. Of particular 83 
relevance for food biopreservation is the potent-antilisteria activity display by the 84 
pediocin-like bacteriocins (Class IIa). Class III comprises large heat labile proteins with 85 
modest prospects as food biopreservatives. With the exception of colicin V and 86 
microcins, Gram negative bacteriocins fall in this class. Finally, circular peptides 87 
characterized by a peptide bond between the C- and N-terminus are clustered in class 88 
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IV. Examples of bacteriocins whose activity resides on the concerted action of two 89 
independent peptides are found in both classes I and II. Most LAB bacteriocins which 90 
have been applied in food biopreservation belong to Class Ia, II and IV (Table 1). 91 
As ribosomally synthesised peptides, bacteriocins are encoded by a plasmid- or 92 
chromosome-borne structural gene which is often clustered with genes coding for 93 
immunity protein(s) and dedicated transport. In particular examples, genes specifying 94 
modification enzymes and regulatory genes may also be present. 95 
 The mode of action of LAB bacteriocins has been extensively studied although 96 
most pioneering work was basically carried out with nisin, the first described Gram 97 
positive bacteriocin. Based on their cationic and their hydrophobic nature, most of these 98 
peptides act as membrane permeabilizers. Pore formation leads to the total or partial 99 
dissipation of the proton motive force, ultimately causing cell death. Bacteriocin pore 100 
formation seems to be target-mediated. Nisin and other lantibiotics use the cell wall 101 
precursor lipid II as a docking molecule (Breukink, Wiedemann, van Kraaij, Kuipers, 102 
Sahl, & de Kruijff, 1999). Thereby, two modes of action, i.e. inhibition of cell wall 103 
biosynthesis and pore formation, are combined within one molecule for potent 104 
antimicrobial activity (Wiedemann et al., 2001). This strategy is also used by other 105 
lantibiotics and non-pore forming bacteriocins such as the non-lantibiotic Lcn972 106 
(Martínez, Böttiger, Schneider, Rodríguez, Sahl, & Wiedemann, 2008a). Recently, 107 
several class II bacteriocins were shown to use the membrane-associated component of 108 
the mannose-phosphotransferase system as specific receptor in target cells (Diep, 109 
Skaugen, Salehian, Holo, & Nes, 2007). 110 
 Many LAB bacteriocins are active against many food-borne and spoilage Gram 111 
positive microorganisms including antibiotic resistant bacteria. Gram negative bacteria 112 
are intrinsically resistant due to the protective role of the external membrane. However, 113 
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some can be active in combination with other membrane destabilizing agents (e.g. 114 
EDTA).  115 
 116 
Current bacteriocin food applications 117 
 The traditional role of LAB on food and feed fermentations is the main load-118 
bearing pillar on which the use of bacteriocins in biopreservation relies. LAB and their 119 
bacteriocins have been consumed unintentionally for ages, laying down a long history 120 
of safe use. Their spectrum of inhibition, bactericidal mode of action, relative tolerance 121 
to technologically relevant conditions (pH, NaCl, heat treatments) and the lack of 122 
toxicity towards eukaryotic cells further support their role as biopreservatives in food. 123 
Since the first use of nisin in the 50´s to inhibit the outgrowth of Clostridium 124 
tyrobutyricum responsible for late cheese blowing, there have been numerous reports in 125 
the literature on the application of many LAB bacteriocins, mostly in food processing. 126 
Excellent comprehensive reviews on bacteriocin-based biopreservation technologies are 127 
available (Gálvez, Abriouel, López, & Ben, 2007; De Arauz, Jozala, Mazzola, & 128 
Vessoni-Penna, 2009; Settanni & Corsetti, 2008). Thus, only a few examples will be 129 
cited to give an overview of bacteriocin applications along the food chain (Fig. 1).  130 
 Examples of bacteriocin application in the production of primary food 131 
commodities are found in veterinary, agriculture and aquaculture. Nisin and lacticin 132 
3147 have been incorporated into commercial prophylactic measures against mastitis. 133 
Bacteriocins have also been suggested as an alternative to antibiotic feeding and the use 134 
of bacteriocin producers able to colonize the gastrointestinal tract has successfully 135 
reduced the carriage of zoonotic pathogens (Calo-Mata, Arlindo, Boehme, de Miguel, 136 
Pascoal, & Barros-Velazquez, 2008; Diez-Gonzalez, 2007; Line et al., 2008). In 137 
aquaculture, most pathogens are Gram negatives and the colicin-like bacteriocins are 138 
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those with the best prospects for biocontrol. Bacterial plant pathogens also synthesised 139 
bacteriocins able to prevent plant infections (Holtsmark, Eijsink, & Brurberg, 2008).  140 
 The largest field of investigation has been the application of bacteriocins to 141 
inhibit pathogenic and spoilage bacteria during food processing (Fig. 1). The 142 
bacteriocins which have been thoroughly examined are the lantibiotics nisin and lacticin 143 
3147, several class IIa or pediocin-like bacteriocins and, among the circular peptides, 144 
enterocin AS-48 has proven to be very effective against a wide range of spoilage and 145 
foodborne pathogens in several foodstuffs including dairy, meat and vegetable products. 146 
Bacteriocins may be applied basically in three different formats: i) in situ production by 147 
starter or protective cultures, ii) as an ingredient (fermentate of a bacteriocinogenic 148 
strain), or iii) as an additive in a semi- or purified preparation. In situ production is 149 
readily cost-effective provided that the bacteriocin producers are technologically 150 
suitable. Nisin-producing dairy starters have been designed to specifically inhibit 151 
Staphylococcus aureus in acid-coagulated cheeses and C. tyrobutyricum in semi-hard 152 
cheeses (Rilla et al., 2003; 2004). Protective cultures, which do not contribute to the 153 
sensory attributes of food, have been mainly applied to enhance the hygienic quality of 154 
raw meat and fish products (Devlieghere, Vermeiren & Debevere, 2004). The use of 155 
bacteriocins as ingredients or additives requires new strategies for large scale 156 
production in suitable low-cost food-grade media. For example, lacticin 3147 and the 157 
enterocin AS-48 have been produced in whey-based media suitable as a dairy ingredient 158 
(Ananou, Muñoz, Gálvez, Martínez-Bueno, Maqueda & Valdivia, 2008; Morgan, 159 
Galvin, Kelly, Ross & Hill, 1999). The use of whey as a substrate is an attractive option 160 
because it also contributes to recycle a by-side product of the dairy industry. 161 
 Besides food biopreservation, bacteriocins have been shown to accelerate cheese 162 
ripening by promoting the release of intracellular enzymes to the cheese matrix and a 163 
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subsequent increase in the concentration of volatile and other compounds responsible of 164 
the sensory attributes of the matured cheese (Martínez-Cuesta, Requena, & Peláez, 165 
2006). Bacteriocins producers were also shown to hold back the adventitious microbiota 166 
and guarantee homogenous fermented products (Ryan, Ross & Hill, 2001). Food grade 167 
markers based on the bacteriocin immunity proteins offer the possibility to replace 168 
antibiotic selective markers for genetic engineering of food-related bacteria (Brede, 169 
Lothe, Salehian, Faye & Nes, 2007).  170 
  171 
Bacteriophages and their antibacterial life cycle. 172 
Bacteriophages or phages are the most abundant microorganisms on Earth (10
31
 173 
particles) and widely spread including foods of various origins (Brüssow and Kutter, 174 
2005). Bacteriophages are viruses that specifically infect and multiply in bacteria. Thus, 175 
they are harmless to humans, animals, and plants. The phages are classified into 13 176 
families based on their shape, size, type of nucleic acid and presence/absence of 177 
envelope or lipids in their structure. Most of them belong to the Caudovirales order 178 
(5360 of 5568 reported to date) with an icosahedral head and a tail and double-stranded 179 
DNA (Fig. 2a). According to the morphological features of the tail, they are classified 180 
into three families: Myoviridae (contractile tail), Siphoviridae (long non contractile tail), 181 
and Podoviridae (extremely short tail). The rest of the phages are cubic, filamentous, or 182 
pleomorphic phages with dsDNA, single-stranded DNA, double-stranded RNA, or 183 
single-stranded RNA (Ackermann, 2007).  184 
Depending on their life style, phages are divided into virulent and temperate 185 
phages (Fig. 2b). Virulent phages strictly follow a lytic cycle whereby they multiply 186 
within the bacterial cell to finally lyse the cell to release the phage progeny. By contrast, 187 
temperate phages may enter the lysogenic cycle by inserting their DNA into the 188 
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bacterial chromosome (prophage) where it replicates as part of the host genome until it 189 
may be induced to enter the lytic cycle. Of note, lysogenic bacteria become immune 190 
against superinfection with the same or a closely related phage. 191 
Several phases are distinguished in the lytic cycle (Fig. 2b). First, host 192 
recognition and adsorption takes place, partly mediated by tail-associated proteins that 193 
distinctively recognize specific bacterial receptors. Upon irreversible adsorption, the 194 
phage injects the nucleic acid that is transcribed by the host cell RNA polymerase. The 195 
phage genome is replicated in multiple copies and the newly synthesised proteins 196 
sequester the entire host cell machinery and force it to exclusively produce the structural 197 
phage proteins, which assemble into the new virions, and lysis proteins which, 198 
ultimately, will lyse the host bacterium.  199 
This last lytic step is precisely where the phage antimicrobial activity resides. In 200 
fact, phages have been extensively used in the former Soviet Union to treat human 201 
infections. Their results undoubtedly indicate that phages are suitable for clinical 202 
treatment or prophylaxis of infectious diseases caused by both Gram positive and Gram 203 
negative bacteria (Sulakvelidze & Kutter, 2005; Hanlon, 2007).  204 
 205 
Current bacteriophage-based food applications 206 
The concept of combating pathogens in food using phages is recent but several 207 
applications along the food chain have already been approached (Fig. 1) and several 208 
companies have already begun investing in phage technology (García, Martínez, Obeso 209 
& Rodríguez, 2008). Bacteriophages are suitable i) to prevent or reduce colonization 210 
and diseases in livestock (phage therapy), ii) to decontaminate carcasses and other raw 211 
products, such as fresh fruit and vegetables, and to disinfect equipment and contact 212 
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surfaces (phage biosanitation), and iii) to extend the shelf life of perishable 213 
manufactured foods as natural preservatives (phage biocontrol). 214 
Phages have been applied to reduce pathogen carriage in livestock farming and 215 
also after slaughter or milking. Several studies have been undertaken to treat chickens 216 
with phages against Salmonella (Fiorentin, Vieira & Barioni, 2005) and Campylobacter 217 
(Atterbury et al., 2005) and to treat ruminants with phages targeted against pathogenic 218 
E. coli (Raya et al., 2006). Significant reduction of bacterial load was observed after 219 
phage treatment, particularly when applied just before slaughtering. Phages were also 220 
active on fresh-cut produce (Leverentz et al., 2003). Another phage-based approach has 221 
been to fight bacterial plant diseases as exemplified by the commercially available 222 
AgriPhage (Intralytix) to combat tomato and pepper spot. In the same line, phage-based 223 
biosanitation has been proposed to reduce biofilm formation (Azeredo & Sutherland, 224 
2008) or to eradicate or reduce S. aureus nasal or skin colonisation in food handlers 225 
(Mann, 2008). 226 
Experimental evidence of the antimicrobial activity of phages during food 227 
processing and storage is still scarce but results are encouraging. The host specificity of 228 
phages, sometimes restricted to a few strains, pose a burden to their wide use as food 229 
biopreservatives. However, it is precisely this feature what makes them very attractive 230 
candidates as biopreservatives in fermented products to avoid interference with proper 231 
starter performance or the development of the secondary microbiota. The incorporation 232 
of phages into milk contaminated with Salmonella in cheddar production reduced viable 233 
cells after storage (Modi, Hirvi, Hill & Griffiths, 2001). Similarly, S. aureus growth in 234 
milk and during curd manufacture was inhibited by phages (García et al., 2007; 2009) 235 
and inhibition proceeded during ripening, and storage of acid coagulated and semi-hard 236 
cheeses (our unpublished results). Complete eradication of Listeria monocytogenes 237 
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depending on dosage and treatment was achieved on surface ripened cheese by surface 238 
application of the virulent phage P100 (Carlton, Noordman, Biswas, de Meester & 239 
Loessner, 2005). Other examples of phage-based biopreservation approaches are 240 
inhibition of Enterobacter sakazakii in reconstituted infant formula milk (Kim, Klumpp 241 
& Loessner, 2007) and Salmonella typhimurium on chicken frankfurters (Whichard, 242 
Sriranganathan & Pierson, 2003). 243 
Recently, two phage cocktails against L. monocytogenes, Listex (EBI Food 244 
Safety, www.ebifoodsafety.com) and LMP 102 (Intralytics, www.intralytics.com) were 245 
approved by the Food and Drug Administration (FDA) in ready-to-eat meat. In 2007, 246 
OmniLytics Inc. (www.omnilytics.com) received FDA approval for an anti-E. coli and 247 
an anti-Salmonella phage-based product to treat live animals prior to slaughtering. 248 
Another contribution of phages to food safety is their use in the detection of 249 
foodborne pathogens. Phages have long been used for bacterial typing and several 250 
phage-based methods have already been developed to detect bacteria in food (Hagens & 251 
Loessner, 2007). These methods basically exploit the phage specificity and the efficacy 252 
of host recognition.  253 
 254 
Endolysins: structure and mode of action 255 
Bacteriophages have developed two basic ways to release the new virions from 256 
the infected bacterial cells. In filamentous bacteriophages the progeny is continuously 257 
extruded from bacteria cells without killing, whereas non-filamentous bacteriophages 258 
destroy the cell wall of the host bacterium by phage-encoded lytic enzymes. Small RNA 259 
and DNA phages encode specific proteins that interfere with host enzymes responsible 260 
for peptidoglycan biosynthesis. In large DNA phages, endolysins (also termed lysins) 261 
are produced during the late phase of gene expression in the lytic cycle and are 262 
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responsible of the enzymatic cleavage of peptidoglycan (Young, Wang & Roof, 2000; 263 
Loessner, 2005). Endolysins are also capable of degrading the peptidoglycan of Gram 264 
positive bacteria when applied externally to the bacterial cell, thereby acting as 265 
antibacterial agents.  266 
Most of the endolysins lack secretory signals and their access to the 267 
peptidoglycan from inside the cell is dependent on small hydrophobic proteins, termed 268 
holins, which enable the endolysin molecules to cross the cytoplasmic membrane and 269 
gain access to the cell wall (Wang, Smith & Young, 2000) (Fig. 3a). A few others 270 
contain signal peptides recognized by the host general secretion pathway (Sao-Jose, 271 
Parreira, Vieira & Santos, 2000). 272 
Depending on the enzymatic specificity, endolysins are divided into five main 273 
classes: i) N-acetylmuramidases (lysozymes), ii) endo-b-N-acetylglucosaminidases, and 274 
iii) lytic transglycosylases, all cleaving at the sugar backbone moiety of peptidoglycan, 275 
iv) endopeptidases, which cleave the peptide moiety, and v) N-acetylmuramoyl-L-276 
alanine amidases, which cut the amide bond between both moieties. Noteworthy, 277 
muramidases and amidases that hydrolyze the most conserved bonds in the 278 
peptidoglycan seem to be the most widely spread (Fischetti, 2008). Peptidoglycan 279 
damage ultimately leads to hypotonic lysis of the host. Some endolysins contain 280 
sequences at the C-terminus similar to those typical of cationic antimicrobial peptides 281 
that disrupt the bacterial membranes (Düring, Porsch, Mahn, Brinkmann & Gieffers, 282 
1999). 283 
Gram positive endolysins display a modular structure composed of at least two 284 
distinct functional domains (Fig. 3b). The N-terminal domain contains the catalytic 285 
activity, mostly with one muralytic activity but bifunctional lysins have also been 286 
described. At the C- terminus, a cell wall binding domain (CBD) confers some degree 287 
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of specificity to the enzyme. Besides, CDBs keep the endolysin bound to its substrate 288 
once the host is lysed. In this way, endolysins are not freely released to the environment 289 
avoiding the lysis of putative new phage host cells. CDBs are not often found among 290 
endolysins from Gram negative phages (Briers et al., 2007). 291 
Most endolysins display a narrow spectrum of lytic activity often restricted to 292 
the host bacterial species of the phage from which it is derived although some are genus 293 
specific. An exception is an enterococcal phage lysin that not only lyses enterococci but 294 
also Streptococcus pyogenes, group B streptococci, and S. aureus, making it one of the 295 
broadest acting lysins identified so far (Yoong, Schuch, Nelson & Fischetti, 2004).  296 
 297 
Endolysins in food applications 298 
Most of work that supports the role of endolysins as powerful antimicrobials has 299 
been focused on prophylaxis and treatment of bacterial infections in animal models. In 300 
regard to food biopreservation, research is still at its infancy. However, the number of 301 
endolysins active against numerous zoonotic and food-borne pathogens which are being 302 
isolated and characterized is increasing exponentially and future applications are 303 
foreseen. Worth mentioning is the fact that to date no resistance to endolysins has been 304 
reported even by repeated exposure or by stimulating mutant development. Although it 305 
may be still premature to be fully confident, lack of resistance is a clear advantage over 306 
other antimicrobial agents. 307 
To date only very few reports have addressed the antimicrobial potential of 308 
endolysins in situ along the food chain. At the primary production step, protection 309 
against the phytopathogen Erwinia amylovora was demonstrated in transgenic potatoes 310 
synthesising the T4 lysozyme (Düring, Porsch, Fladung & Lörz, 1993) or by surface 311 
application of the recombinant phiEa1h endolysin on pears (Kim, Salm & Geider, 312 
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2004). Transgenic cows expressing endolysins have also been suggested to reduce 313 
mastitis and S. aureus milk contamination (Donovan, Lardeo & Foster-Frey, 2006). As 314 
a prophylactic measurement, aerosolized PlyC endolysin contributed to eradicate or 315 
reduce Streptococcus equi load on a variety of materials even in the presence of non 316 
ionic detergents, hard water, or organic materials (Hoopes, Stark, Kim, Sussman, 317 
Donovan & Nelson, 2009). Likewise, a staphylococcal endolysin has been shown to 318 
remove S. aureus biofilms (Sass & Bierbaum, 2007).  319 
In food processing, pathogen biocontrol by endolysins has been basically 320 
approached in dairy manufacturing. Pioonering work has been carried out with the 321 
staphylococcal phage endolysin LysH5 (Obeso, Martínez, Rodríguez & García, 2008). 322 
The purified endolysin killed S. aureus in pasteurized milk, although higher amounts 323 
than those anticipated in vitro were needed. Recombinant lactic acid bacteria were able 324 
to secrete active Listeria endolysin but their antagonistic activity in milk or alternative 325 
food matrices has not been assessed (Turner, Waldherr, Loessner & Giffard, 2007). 326 
A very relevant role that endolysins play in food safety is based on the high 327 
specificity of their CBDs. These recognition domains have been used to develop rapid 328 
and sensitive identification and detection systems (Fujinami, Hirai, Sakai, Yoshino & 329 
Yasuda, 2007). Magnetic beads coated with recombinant CBDs enabled immobilization 330 
and recovery of more than 90% of L. monocytogenes cells from food samples (Kretzer 331 
et al., 2007).  332 
 333 
Topics for the future 334 
 Despite of the vast knowledge generated on bacteriocin and bacteriophage 335 
biology and the increasing attention paid to endolysins, there are still several basic and 336 
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applied issues that deserve further attention to fully exploit their antimicrobial potential 337 
in food safety (Table 2).  338 
Special needs in basic research may be grouped in three main fields: i) resistant 339 
mechanisms, ii) new and/or enhanced antimicrobials, and iii) safety concerns which 340 
may emerge by the use of these biopreservatives. Development of resistance is a major 341 
concern when designing new biopreservation approaches. Adaptation to bacteriocins is 342 
easily achieved under laboratory conditions. Besides, little is known about bacteriocin 343 
immunity and the chance of genetic transfer. Noteworthy, despite of the extensive use 344 
of nisin as a food biopreservative, resistance has not posed a problem yet. Nevertheless, 345 
the consequences of adaptation to bacteriocins must be considered when designing 346 
combined treatments as cross-resistant phenomena may occur (Martínez, Obeso, 347 
Rodríguez & García, 2008b). High-throughput technologies (omics) will help to clarify 348 
how cells respond to bacteriocin treatment. Resistance could also threaten 349 
bacteriophage-based approaches. However, phage resistance may reduce the fitness or 350 
virulence of the bacteria and the use of phages mixtures decrease the probability of 351 
resistance. Moreover, phages mutate at frequencies significantly higher than that of 352 
bacteria and selection of new phages might easily overcome bacterial resistance. 353 
Lysogeny also makes bacteria resistant to superinfection, thereby temperate phages 354 
should be avoided.  355 
Current molecular biology techniques and the genetic amenability of 356 
bacteriocins, phages and endolysins offer attractive options to develop new 357 
antimicrobials. Bacteriocins and endolysins are suitable for DNA shuffling and protein 358 
engineering to generate highly potent variants with expanded activity spectrum (Field, 359 
Connor, Cotter, Hill & Ross, 2008; Manoharadas, Witte & Bläsi, 2009). Bacteriophages 360 
may be also genetically modified to fullfill specific requirements such as an expanded 361 
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host range. Moreover, phages encode other proteins or peptides that inhibit the bacterial 362 
growth during infection as well as virion-associated peptidoglycan hydrolases 363 
responsible for “lysis from without” and enzymes involved on degradation of surface 364 
polysaccharides. All of them might be regarded as future antimicrobials.  365 
Considering the use of bacteriocins, bacteriophages and endolysins as food 366 
additives, it is important to address the effect of oral administration. The inclusion of 367 
bacteriocinogenic strains in probiotic preparations demands a better knowledge of the 368 
ecological role that bacteriocins may play in complex ecosystems as the gastrointestinal 369 
tract (e.g. outcompeting pathogens) (Corr, Li, Riedel, O'Toole, Hill & Gahan, 2007). 370 
The new molecular tools to study the intestinal microbiome will definitively be very 371 
useful. More detailed cytotoxic and immunogenicity studies are also needed 372 
(Jasniewski, Cailliez-Grimal, Chevalot, Milliere & Revol-Junelles, 2009). So far, no 373 
adverse effects of oral administration of phages have been described (Bruttin & Brüsow, 374 
2005). On the contrary, no data are available about endolysins, although no signs of 375 
anaphylaxis were observed after both systemic and mucosal administration (Fischetti, 376 
2008). Other safety issues related to the use of phages must be carefully analysed prior 377 
to selecting biopreservation candidates. This includes a deep knowledge of the role of 378 
phages in DNA exchange and virulence. Phages may carry harmful genes and some 379 
may even promote intergeneric transfer (Cheng & Novick, 2009). 380 
 From a practical point of view, a major effort is needed to enhance the 381 
effectiveness of these biopreservatives in the food matrix as their antimicrobial activity 382 
may be extremely disminished in situ. Food composition, microbial load, and 383 
technological treatments have already been shown to interfere largely with bacteriocin 384 
activity (reviewed by Gálvez et al., 2007). It also applies to phages as infection proceeds 385 
upon contact with the host, clearly hindered in solid or semi-solid environments such as 386 
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food. Many other variables such as adsorption rate, burst size, latent period, initial 387 
phage dose, bacterial concentration, etc. are also involved. All these critical parameters 388 
may be modelled (Cairns, Timms, Jansen, Connerton & Payne, 2009). However, a 389 
deeper insight into the dynamics of phage infection in different food matrices is still 390 
missing.  391 
Currently, efforts to improve preservation technologies are mainly focused on 392 
hurdle technology. Bacteriocins have been succesfully combined with other hurdles. 393 
They have been incorporated into packaging films and combined with modified 394 
atmosphere packaging (MAP). Bacteriocins also help to apply less harsh conditions of 395 
traditional preservation methods (i.e. less chemical preservatives or lower heat 396 
treatments) with the subsequent energy and costs saving. They also act synergistically 397 
with emerging preservation technologies such as high hydrostatic pressure and pulsed 398 
electric fields showing synergic effects (Gálvez et al., 2007). On the contrary, the use of 399 
phages and endolysins in hurdle technology has hardly been explored but results are 400 
promising. Phages and endolysins have been successfully combined with nisin and high 401 
hydrostatic pressure enhanced endolysin activity by making the peptidoglycan of Gram 402 
negatives accessible (Briers et al., 2008). Bacteriophages and endolysins have been 403 
proposed as disinfectants in food environments, including food handlers, but delivery 404 
strategies have to be implemented. 405 
Within the food chain, there are several unexploited fields in which these natural 406 
antimicrobials may be relevant. For example, the use of bacteriocinogenic starter for 407 
silage fermentation has hardly been addressed. Moreover, these natural antimicrobials 408 
are suitable for organic food production, thereby promoting an environmentally 409 
responsible food industry. 410 
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It is expected that a better and deeper understanding of the molecular basis of the 411 
antimicrobial activity of bacteriocins, bacteriophages and endolysins will definitively 412 
result in safer food in the near future. Following a knowledge-based approach, new 413 
biopreservation strategies as well as unique biotechnological applications of these 414 
natural antimicrobials are envisaged. 415 
 416 
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Figure captions 628 
 629 
Figure 1. Proposed bacteriocin, bacteriophages and endolysin applications of their 630 
antimicrobial activitiy along three main stages of the food chain (based on published 631 
reports). 632 
Figure 2. Structure of a typical tailed bacteriophage (a) and the steps during the 633 
bacteriophage lytic and lysogenic life cycles (b). Temperate phages may follow the 634 
lysogenic cycle by integration into the host genome. After infection, or prophage 635 
activation, the host is lysed to release the new progeny.  636 
Figure 3. Schematic representation of the modular structure (a) and mode of action (b) 637 
of phage-encoded-endolysins. Most endolysins are characterized by one or two catalytic 638 
domains and one cell wall binding domain involved in substrate recognition. Access of 639 
the endolysin to the peptidoglycan (PG) layer is often aided by insertion of the holin 640 




 Table 1. Bacteriocin classification according to Heng and Tagg (2006). 
Class General features Produced by lactic acid bacteria 
I-Lantibiotics Modified, heat stable, <15 kDa  
Ia-Linear Pore forming, cationic Nisin, Lacticin 481, Plantaricin C 
Ib-Globular Enzyme inhibitors, no cationic None 
IIc-Multi-component Two peptides Lct3147, Plantaricin W 
   
II-Unmodified peptides Heat stable, <15 kDa  
IIa-Pediocin-like anti-listeria, YGNGV consensus Pediocin PA1/AcH, Enterocin A, Sakacin A 
IIb-Miscellaneous Non-pediocin-like Enterocin B, L50, Carnobacteriocin A 
IIc- Multi-component Two peptides Lactococcin G, Plantaricin S, Lactacin F 
   
III-Large proteins Heat labile, >30 kDa  
IIIa-Bacteriolytic Cell wall degradation Enterolysin A, Lcn972
a 
IIIb-Non-lytic Cytosolic targets Colicins
b
 E2-E9 
   
IV-Circular peptides Heat stable, tail-head peptide bond AS-48, Gassericin A, Acidocin B 
a
 Lcn972 binds to the cell wall precursor lipid II and blocks cell wall biosynthesis, 15 kDa. 
b
 Colicins are synthesised by E. coli. 
 
 
 Table 2. Research topics on bacteriocins, bacteriophages and endolysins to be addressed in 
the future. 
Topic Specific issues 
Basic Research Bacteriocins Phage/endolysins 
Resistant mechanisms Transfer of  immunity; cross 
resistance; bacteriocin receptors 
Lysogeny, molecular basis of host 
specificity and frequency of mutations 
   
New antimicrobials Protein engineering Unknown phage proteins with 
antimicrobial activity/domain shuffling 
   
Safety Effects in complex ecosystems (GT, 
fermented foods); toxicity 
Role of phages in DNA exchange and 
host virulence; toxicityy 
   
Applied Research Bacteriocins/phage/endolysins 
Food processing Influence of the food matrix and food processing (modelling) 
Use in hurdle technology 
Biofilm removal and Biosanitation 
  
Unexploited fields Silage, organic production 










Alternative to antibiotic-based 
growth promoters
Reduction of zoonotic bacteria
In situ production (starter/protective 
cultures) or additive/food ingredient
Processing aids in cheese ripening 
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